SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Tavelin Björn)
 

Sökning: WFRF:(Tavelin Björn) > Type IV collagen as...

Type IV collagen as a potential biomarker of metastatic breast cancer

Lindgren, Moa (författare)
Umeå universitet,Kirurgi,Norrlands Universitetssjukhus
Jansson, Malin (författare)
Umeå universitet,Kirurgi,Norrlands Universitetssjukhus
Tavelin, Björn (författare)
Umeå universitet,Onkologi
visa fler...
Dirix, Luc (författare)
Translational Cancer Research Unit, GZA Hospital Sint Augustinus and Antwerp University, Antwerp, Belgium
Vermeulen, Peter (författare)
Translational Cancer Research Unit, GZA Hospital Sint Augustinus and Antwerp University, Antwerp, Belgium
Nyström, Hanna, 1980- (författare)
Umeå universitet,Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM),Kirurgi,Translational Cancer Research Unit, GZA Hospital Sint Augustinus and Antwerp University, Antwerp, Belgium; Norrlands Universitetssjukhus
visa färre...
 (creator_code:org_t)
2021-03-03
2021
Engelska.
Ingår i: Clinical and Experimental Metastasis. - : Springer. - 0262-0898 .- 1573-7276. ; 38:2, s. 175-185
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • No reliable, non-invasive biomarker of metastatic breast cancer (mBC) exists: circulating CA15-3 (cCA15-3) is the marker mostly used to monitor mBC. Circulating collagen IV (cCOLIV) has been evaluated in other metastatic cancers and has been found to be a promising biomarker. The overarching aim of this study was to evaluate cCOLIV as a potential biomarker in patients with mBC. The first aim was to determine the levels of cCOL IV and cCA15-3 in patients with healthy controls, primary breast cancer (pBC) and mBC. The second aim was to compare levels of cCOLIV and cCA15-3 in patients with different metastatic sites of BC. The third aim was to investigate the prognostic value of cCOLIV and cCA15-3 for mBC patients. The fourth aim was to analyse whether a combination of the two biomarkers was more accurate in detecting mBC than a single marker. Lastly, we investigated the tissue expression levels of COLIV in BC bone metastases (BM) and liver metastases (LM). Plasma levels of cCOLIV and cCA15-3 from healthy controls and patients with pBC and mBC were measured. COLIV expression in tissue from patients with LM and BM was analysed using immunohistochemistry. Clinical and survival data were collected from medical charts. The levels of cCOLIV and cCA15-3 were significantly elevated in mBC patients compared with healthy controls and pBC patients. No differences in cCOLIV and cCA15-3 levels were found based on the metastatic site. High levels of cCOLIV, but not cCA15-3, correlated with poorer survival. cCOLIV alone and the combination of cCA15-3 and cCOLIV were superior to cCA15-3 at detecting mBC. COL IV was highly expressed in the tissue of LM and BM. Our study suggests that cCOLIV is a potential marker to monitor patients with BC.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Biomarkers
Breast cancer
CA 15-3
Collagen IV
Metastases

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy